Neurogene, Inc. Common Stock
$32.09
-$0.32 (-0.99%)
$31.86Day Range$33.15
Key Statistics
Market Cap
$648.57M
Shares Outstanding
20.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 19, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$32.49
Day High
$33.15
Day Low
$31.86
Volume
1.39M
VWAP
$32.13
Prev Close
$32.41
Transactions
--
Acc. Volume
--
About Neurogene, Inc. Common Stock
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
PHARMACEUTICAL PREPARATIONSSIC 2834131 employees535 W 24TH STREET, NEW YORK, NY, 10011(877) 237-5020IPO Dec 19, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001404644
- Composite FIGI
- BBG005Y0QDK1
- Share Class FIGI
- BBG005Y0QF99
- Ticker Root
- NGNE
- SIC Code
- 2834
About Neurogene, Inc. Common Stock (NGNE) Stock
Neurogene, Inc. Common Stock (NGNE) closed the 2026-09-18 session at $32.09, down 0.99% versus the previous close (-0.32). The stock opened at $32.49 and traded between $31.86 and $33.15 during that session. Session trading volume was 1.4M shares. The volume-weighted average price (VWAP) is $32.13.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Neurogene, Inc. Common Stock has a market capitalization of $648.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NGNE is listed on the XNAS exchange. The company employs approximately 131 people. Neurogene, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2023-12-19.
On this page you can find market NGNE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.